Real-world analysis of immunochemotherapy in recurrent small-cell lung cancer: opportunities for second-line approaches.

Front Pharmacol · 2025 · PMC12162476 · PMID 40520158

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although not statistically significant, our data showed a trend toward improved OS in patients who received immunotherapy rechallenge (12.77 vs. 9.17 months), consistent with previous studies.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.